COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks

COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks

In line with SARS and MERS, the SARS-CoV-2/COVID-19 pandemic is one of the largest challenges in medicine and health care worldwide. SARS-CoV-2 infection/COVID-19 provides numerous therapeutic targets, each of them promising, but not leading to the success of therapy to date. Neither an antiviral no...

Full description

Bibliographic Details
Main Authors:	Markus Blaess, Lars Kaiser, Martin Sauer, René Csuk, Hans-Peter Deigner
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	International Journal of Molecular Sciences
Subjects:	SARS-CoV-2 COVID-19 lysosomotropic compounds lysosome cytokine storm cytokine release syndrome
Online Access:	https://www.mdpi.com/1422-0067/21/14/4953

Similar Items

Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19
by: Markus Blaess, et al.
Published: (2020-11-01)

Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19
by: Markus Blaess, et al.
Published: (2021-02-01)

Drug triggered pruritus, rash, papules, and blisters – is AGEP a clash of an altered sphingolipid-metabolism and lysosomotropism of drugs accumulating in the skin?
by: Markus Blaess, et al.
Published: (2021-11-01)

Small molecules targeting endolysosomal acidification and signaling in sepsis and severe SARS-CoV-2 infection/COVID-19
by: Markus Blaess, et al.
Published: (2022-08-01)

The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane
by: Michal Stark, et al.
Published: (2020-04-01)

Lysosomotropic Features and Autophagy Modulators among Medical Drugs: Evaluation of Their Role in Pathologies
by: Tatiana A. Korolenko, et al.
Published: (2020-10-01)

The lysosomotropic drug LeuLeu-OMe induces lysosome disruption and autophagy-independent cell death in Trypanosoma brucei
by: Hazel Xinyu Koh, et al.
Published: (2015-07-01)

Interactions of the Lysosomotropic Detergent O-Methyl-Serine Dodecylamide Hydrochloride (MSDH) with Lipid Bilayer Membranes—Implications for Cell Toxicity
by: Ana-Maria Villamil Giraldo, et al.
Published: (2020-04-01)

Lysosomal membrane integrity in fibroblasts derived from patients with Gaucher disease
by: Asuka Hamamoto, et al.
Published: (2023-12-01)

Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics
by: Allemailem KS, et al.
Published: (2021-07-01)

Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2
by: Wang LG, et al.
Published: (2022-05-01)

Drug Sequestration in Lysosomes as One of the Mechanisms of Chemoresistance of Cancer Cells and the Possibilities of Its Inhibition
by: Jan Hraběta, et al.
Published: (2020-06-01)

Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections
by: Liu T, et al.
Published: (2021-10-01)

Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review
by: Khalid Eljaaly, et al.
Published: (2021-06-01)

Immunomodulating Phytochemicals: An Insight Into Their Potential Use in Cytokine Storm Situations
by: Abdusalam Abdullah Alarabei, et al.
Published: (2024-03-01)

The Many Faces of JAKs and STATs Within the COVID-19 Storm
by: Alice H. Grant, et al.
Published: (2021-07-01)

A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19?
by: Monique Aucoin, et al.
Published: (2021-09-01)

An adaptable in vitro cytokine release assay (CRA): Susceptibility to cytokine storm in COVID-19 as a model
by: Masih Alam, et al.
Published: (2022-01-01)

Cytokine release syndrome
by: Alexander Shimabukuro-Vornhagen, et al.
Published: (2018-06-01)

Mixed storm in SARS‐CoV‐2 infection: A narrative review and new term in the Covid‐19 era
by: Basil Mohammed Alomair, et al.
Published: (2023-04-01)

Immune Responses to SARS-CoV2 Mirror Societal Responses to COVID-19: Identifying Factors Underlying a Successful Viral Response
by: Shahar Lev-Ari, et al.
Published: (2021-05-01)

Immune responses in SARS-CoV-2, SARS-CoV, and MERS-CoV infections: A comparative review
by: Soussan Irani
Published: (2022-01-01)

Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions
by: Robert Root-Bernstein
Published: (2021-02-01)

Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19
by: Gábor Kökény, et al.
Published: (2023-01-01)

Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial and Lysosomal Function
by: Marco Varalda, et al.
Published: (2020-10-01)

The Human Monocyte—A Circulating Sensor of Infection and a Potent and Rapid Inducer of Inflammation
by: Sandra Lara, et al.
Published: (2022-03-01)

Lysosomal acidification dysfunction in microglia: an emerging pathogenic mechanism of neuroinflammation and neurodegeneration
by: Joseph D. Quick, et al.
Published: (2023-08-01)

Determining the disease outcome by cytokine storm during infectious diseases and targeting cytokines during Sepsis: Possible therapeutic options
by: Tasbir Amin, et al.
Published: (2022-12-01)

Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System
by: Puneet Kaur Randhawa, et al.
Published: (2020-11-01)

The Immunopathology of COVID-19 and the Cannabis Paradigm
by: Nicole Paland, et al.
Published: (2021-02-01)

Dysregulated immune response in SARS-CoV-2 infections
by: Marilaeta Cindryani, et al.
Published: (2020-01-01)

Potential effects of hydroxysafflor yellow A on reducing pulmonary inflammation and fibrosis due to SARS-COV2
by: Ami Febriza, et al.
Published: (2022-12-01)

Lessons Learned Comparing Immune System Alterations of Bacterial Sepsis and SARS-CoV-2 Sepsis
by: Xijie Dong, et al.
Published: (2020-11-01)

Calcineurin inhibitors revisited: A new paradigm for COVID-19?
by: René Hage, et al.
Published: (2020-07-01)

1-Benzyl-3-cetyl-2-methylimidazolium Iodide (NH125) Is a Broad-Spectrum Inhibitor of Virus Entry with Lysosomotropic Features
by: Sarah Moeschler, et al.
Published: (2018-06-01)

Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review
by: Vincenzo Lariccia, et al.
Published: (2020-12-01)

Coronavirus Disease (COVID-19–SARS-CoV-2) and Nutrition: Is Infection in Italy Suggesting a Connection?
by: Hellas Cena, et al.
Published: (2020-05-01)

Current Perspective on Vitamins and SARS-CoV-2 Disease (COVID-19)
by: Himanshi Goyal, et al.
Published: (2023-10-01)

Through DNA sensors and hidden mitochondrial effects of SARS-CoV-2
by: Vitor Pedro Targhetta, et al.
Published: (2021-08-01)

The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection
by: Douglas L. Archer, et al.
Published: (2020-06-01)